Public Open Comment: Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors – Revision Draft Recommendations

PUBLIC OPEN COMMENT

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) Update (Lung Guideline Update Project)

Draft Recommendations

The public open comment period will close SEPTEMBER 12, 2024 at 11:59 PM Eastern (US).

Thank you again for contributing your time and expertise to the Lung Guideline Update Draft Recommendations development process during this open comment period. All comments will be returned to the Lung Guideline Expert Panel for consideration and evaluation. We look forward to your feedback to further enhance the final recommendations.

Project Co-Chairs:

Sinchita Roy-Chowdhuri, MD, PhD on behalf of CAP

Sanja Dacic, MD, PhD on behalf of IASLC

Neal Lindeman, MD on behalf of AMP